To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 25 June to Question 61301 on Alzheimer's Disease: Drugs, whether NICE has made an assessment of the potential impact of not publishing the economic models for (a) lecanema
The National Institute for Health and Care Excellence’s (NICE) single technology appraisal process relies on information provided by companies to evaluate the clinical and cost-effectiveness of new treatments. Some of this information, including the econo...
Alzheimer's Disease: Drugs